

Lara Magro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1336205/publications.pdf>

Version: 2024-02-01

13
papers

702
citations

1040056

9
h-index

1474206

9
g-index

13
all docs

13
docs citations

13
times ranked

1036
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of phenolic compounds and radical scavenging activity of Echinacea spp.. Journal of Pharmaceutical and Biomedical Analysis, 2004, 35, 289-301.	2.8	241
2	Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opinion on Drug Safety, 2012, 11, 83-94.	2.4	192
3	Identifying Adverse Drug Reactions Associated with Drug-Drug Interactions. Drug Safety, 2010, 33, 667-675.	3.2	77
4	Effect of Pharmacist Involvement on Patient Reporting of Adverse Drug Reactions: First Italian Study. Drug Safety, 2013, 36, 267-276.	3.2	43
5	What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects. Drug Safety, 2018, 41, 1003-1011.	3.2	42
6	Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy. Expert Opinion on Drug Safety, 2014, 13, 21-29.	2.4	38
7	Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. European Journal of Clinical Pharmacology, 2010, 66, 199-206.	1.9	35
8	Fluvastatin and Hepatic Reactions. Drug Safety, 2006, 29, 1163-1172.	3.2	18
9	Identifying and Characterizing Serious Adverse Drug Reactions Associated With Drug-Drug Interactions in a Spontaneous Reporting Database. Frontiers in Pharmacology, 2020, 11, 622862.	3.5	16
10	Lormetazepam Addiction. , 2016, , 273-282.		0
11	Italian monitoring registries: a tool for a safer use of innovative drugs? Data from the national pharmacovigilance system. Expert Opinion on Drug Safety, 2016, 15, 69-75.	2.4	0
12	Reporting of immune checkpoint inhibitor-associated myocarditis. Lancet, The, 2018, 392, 383-384.	13.7	0
13	Rilevanza clinica e aspetti medico-legali delle interazioni tra farmaci. Pratica Medica & Aspetti Legali, 2012, 6, 43-50.	0.0	0